Aipharma signs binding agreement to sell to aditxt inc (nasdaq: adtx). aipharma is the rights holder of antiviral tablet avigan / reeqonus / qifenda that has treated over 1.5m covid-19 patients since the outbreak.

Dubai, united arab emirates, oct. 5, 2021 /prnewswire/ -- aipharma global holdings llc ("aipharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement to sell all of its assets through the sale of one of its wholly owned group subsidaries, to aditxt inc. (nasdaq: adtx). aditxt is a biotech innovation company with a mission to improve the health of the immune system.
RDY Ratings Summary
RDY Quant Ranking